Co-Diagnostics (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal and Sri Lanka. The expansion significantly increases CoSara's addressable market to an estimated $13.0 billion, according to the company's press release.
The expansion supports the planned commercialization of the CoSara PCR Pro point-of-care platform and the SARAGENE product line, subject to regulatory approvals. The company is building regional distribution channels and positioning for broader deployment of its molecular diagnostics solutions across the newly added territories.
Co-Diagnostics, based in Utah, is a molecular diagnostics company that develops, manufactures and markets diagnostics technologies. The company's technologies are utilized for tests designed using the detection and analysis of nucleic acid molecules (DNA or RNA). The company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform, which is subject to regulatory review and not currently for sale, and to identify genetic markers for use in applications other than infectious disease.
The expansion into Bangladesh, Pakistan, Nepal and Sri Lanka marks a strategic move to capture a larger share of the South Asian diagnostics market. These countries have significant unmet needs for affordable and accessible molecular diagnostics, particularly in infectious disease testing. The CoSara PCR Pro platform is designed to deliver rapid, accurate results at the point of care, which could improve patient outcomes and reduce the burden on centralized laboratories.
For more information about the expansion, view the full press release at https://ibn.fm/2aATV.
Additional information about Co-Diagnostics is available at https://co-dx.com/.
This announcement comes as Co-Diagnostics continues to navigate the regulatory landscape in various countries. The company's forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, involve risks and uncertainties that could cause actual results to differ materially. These risks are detailed in the company's filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
